NCT03839342: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

NCT03839342
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Tumor must express one of the following BRAF alterations: BRAF mutation (affecting codons: 241, 257, 367, 462, 463, 464, 466, 467, 469, 485, 581, 586, 594, 595, 596, 597 598, 599, 601), V600 BRAF mutations, BRAF deletions, BRAF insertions, BRAF fusions – see trial for details
Exclusions: Patients with leptomeningeal disease and/or symptomatic unstable brain metastasis that require therapy- see trial for details; Patients with a tumor expressing a BRAF V600E mutation; Prior therapy with any BRAF or MEK inhibitor
https://ClinicalTrials.gov/show/NCT03839342

Comments are closed.

Up ↑